Inflammation-induced angiogenesis is closely related to many diseases and has been regarded as a therapeutic target.
Caspase-8 has attracted increasing attention for its immune properties and therapeutic potential in inflammatory disorders. The aim of our study is to investigate the clinical application of pharmacological inhibition of
caspase-8 and the underlying molecular mechanisms in
inflammation-induced angiogenesis in the cornea. A model of
alkali burn (AB)-induced
corneal neovascularization (CNV) in C57BL/6 wild-type (WT) mice and
toll-like receptor 4 knockout (Tlr4-/-) mice was used. We found that AB increased
caspase-8 activity and the pharmacological inhibition of
caspase-8 exerted substantial inhibitory effects on CNV, with consistent decreases in
caspase-8 activity, inflammatory cell infiltration, macrophage recruitment and activation,
VEGF-A, TNF-α, IL-1β, MIP-1, and MCP-1 expression in the cornea. In vitro,
caspase-8 mediated TLR4-dependent
chemokines and
VEGF-A production by macrophages. The TLR4 knockout significantly alleviated CNV, suppressed
caspase-8 activity and downregulated expression of inflammatory
cytokines and
chemokines after AB. Taken together, these findings provide the first demonstration that the pharmacological inhibition of
caspase-8 suppresses
inflammation-induced angiogenesis and support the use of a pharmacological
caspase-8 inhibitor as a novel clinical treatment for CNV and other angiogenic disorders.